Minimizing Cardiac Risks With Contemporary Radiation Therapy for Hodgkin Lymphoma [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 12, 2016 Category: Cancer & Oncology Authors: Maraldo, Ng Tags: Radiation, Radiation Oncology EDITORIALS Source Type: research

Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 12, 2016 Category: Cancer & Oncology Authors: Offer, Diasio Tags: EDITORIALS Source Type: research

To RCT or Not to RCT: How to Change Practice for Rare Cancers? [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 12, 2016 Category: Cancer & Oncology Authors: Brade, Dawson Tags: Clinical Trials, Radiation, Combined Modality, Radiation Oncology EDITORIALS Source Type: research

Acute Radiation Skin Toxicity Associated With BRAF Inhibitors [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 12, 2016 Category: Cancer & Oncology Authors: Pulvirenti, Hong, Clements, Forstner, Suchowersky, Guminski, McNeil, Hersey, Fogarty, Kefford, Long, Wang Tags: Diagnosis & Staging, Radiation, Combined Modality, Translational Oncology, Radiation Oncology DIAGNOSIS IN ONCOLOGY Source Type: research

Familial GI Stromal Tumor With Loss of Heterozygosity and Amplification of Mutant KIT [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 12, 2016 Category: Cancer & Oncology Authors: Forde, Cochran, Boikos, Zabransky, Beaver, Meyer, Thornton, Montgomery, Lidor, Donehower, Park Tags: Translational Oncology DIAGNOSIS IN ONCOLOGY Source Type: research

Nodular Regenerative Hyperplasia After Treatment With Trastuzumab Emtansine [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 12, 2016 Category: Cancer & Oncology Authors: Force, Saxena, Schneider, Storniolo, Sledge, Chalasani, Vuppalanchi Tags: Chemotherapy, Combined Modality, Hormonal Therapy, Translational Oncology, Phase I and Clinical Pharmacology, CT, Breast Imaging, Breast Cancer, Gene Expression and Profiling, Growth Factors & Receptor, Oncogenes, Phase I and Clinical Pharmacology DIAGN Source Type: research

Advertising [Oncology Career Center]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 11, 2016 Category: Cancer & Oncology Tags: Oncology Career Center Source Type: research

Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Menon, Kalsi, Gentry-Maharaj, Ryan, Burnell, Parmar, Fallowfield, Campbell, McGuire, Skates, Jacobs Tags: CORRESPONDENCE Source Type: research

Ovarian Cancer Early Detection Needs Better Imaging, Not Better Algorithms or Biomarkers [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: McIntosh, Drescher, Fitzgibbon Tags: CORRESPONDENCE Source Type: research

Preventing Ovarian Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Crum Tags: CORRESPONDENCE Source Type: research

Definition of Specificity in a Screening Trial [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Pinsky Tags: CORRESPONDENCE Source Type: research

Reply to B. Jeremic et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Bezjak, Temin, Azzoli Tags: CORRESPONDENCE Source Type: research

No Role For Trimodality Therapy and Consolidation Chemotherapy Compared With Concurrent Radiochemotherapy Alone in Stage III Non-Small-Cell Lung Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Jeremic, Cihoric, Casas, Gomez-Caamano, Dubinsky Tags: CORRESPONDENCE Source Type: research

Patchwork [ART OF ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Billington Tags: Emotions of the oncologist, All Art of Oncology Articles Source Type: research

Barriers to a Career Focus in Cancer Prevention: A Report and Initial Recommendations From the American Society of Clinical Oncology Cancer Prevention Workforce Pipeline Work Group [SPECIAL ARTICLE]
Conclusion Reluctance to incorporate cancer prevention into an oncology career seems to stem from lack of mentors and exposure during training, unclear career path, and uncertainty regarding reimbursement. Suggested approaches to begin to remedy this problem include: 1) more ASCO-led and other prevention educational resources for fellows, training directors, and practicing oncologists; 2) an increase in funded training and clinical research opportunities, including reintroduction of the R25T award; 3) an increase in the prevention content of accrediting examinations for clinical oncologists; and 4) interaction with policym...
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Fabian, Meyskens, Bajorin, George, Jeter, Khan, Tyne, William Tags: Quality of Care, Quality of Care SPECIAL ARTICLE Source Type: research

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 [ASCO SPECIAL ARTICLE]
Purpose An American Society of Clinical Oncology Provisional Clinical Opinion (PCO) offers timely clinical direction after publication or presentation of potentially practice-changing data from major studies. This PCO update addresses the utility of extended RAS gene mutation testing in patients with metastatic colorectal cancer (mCRC) to detect resistance to anti–epidermal growth factor receptor (EGFR) monoclonal antibody (MoAb) therapy. Clinical Context Recent results from phase II and III clinical trials in mCRC demonstrate that patients whose tumors harbor RAS mutations in exons 2 (codons 12 and 13), 3 (codons 5...
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Allegra, Rumble, Hamilton, Mangu, Roach, Hantel, Schilsky Tags: ASCO Guidelines, Epidemiology, Diagnosis & Staging ASCO SPECIAL ARTICLE Source Type: research

Survival Impact of Increasing Time to Treatment Initiation for Patients With Head and Neck Cancer in the United States [Head and Neck Cancer]
Purpose To estimate the overall survival (OS) impact from increasing time to treatment initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC). Methods Using the National Cancer Data Base (NCDB), we examined patients who received curative therapy for the following sites: oral tongue, oropharynx, larynx, and hypopharynx. TTI was the number of days from diagnosis to initiation of curative treatment. The effect of TTI on OS was determined by using Cox regression models (MVA). Recursive partitioning analysis (RPA) identified TTI thresholds via conditional inference trees to estimate the greatest diffe...
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Murphy, Galloway, Handorf, Egleston, Wang, Mehra, Flieder, Ridge Tags: Epidemiology, Surgery, Radiation, Combined Modality Head and Neck Cancer Source Type: research

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant-Associated Anaplastic Large-Cell Lymphoma [Hematologic Malignancy]
Conclusion Surgical management with complete surgical excision is essential to achieve optimal EFS in patients with BI-ALCL. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Clemens, Medeiros, Butler, Hunt, Fanale, Horwitz, Weisenburger, Liu, Morgan, Kanagal-Shamanna, Parkash, Ning, Sohani, Ferry, Mehta-Shah, Dogan, Liu, Thormann, DiNapoli, Lade, Piccolini, Reyes, Williams, McCarthy, Hanson, Nastoupil, Gaur, Oki, Young, Miran Tags: Diagnosis & Staging, Surgery, Causality, Diagnosis & Staging, Surgical Oncology Hematologic Malignancy Source Type: research

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease [Hematologic Malignancy]
Conclusion The results of this study suggest that patients with PV who have any one of the features in question (known HU use, known phlebotomy, or splenomegaly) have significant PV-associated symptoms. Furthermore, it demonstrates that many PV symptoms remain severe independent of the number of features present. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Geyer, Scherber, Kosiorek, Dueck, Kiladjian, Xiao, Slot, Zweegman, Sackmann, Fuentes, Hernandez-Maraver, Dohner, Harrison, Radia, Muxi, Besses, Cervantes, Johansson, Andreasson, Rambaldi, Barbui, Bonatz, Reiter, Boyer, Etienne, Ianotto, Ranta, Roy, Cahn, Tags: Translational Oncology, Quality of Life Hematologic Malignancy Source Type: research

Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database [Gastrointestinal Cancer]
Purpose In recent retrospective analyses of early-stage colorectal cancer (CRC), low and high body mass index (BMI) scores were associated with worsened outcomes. Whether BMI is a prognostic or predictive factor in metastatic CRC (mCRC) is unclear. Patients and Methods Individual data from 21,149 patients enrolled onto 25 first-line mCRC trials during 1997 to 2012 were pooled. We assessed both prognostic and predictive effects of BMI on overall survival and progression-free survival, and we accounted for patient and tumor characteristics and therapy type (targeted v nontargeted). Results BMI was prognostic for overall survival (P
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Renfro, Loupakis, Adams, Seymour, Heinemann, Schmoll, Douillard, Hurwitz, Fuchs, Diaz-Rubio, Porschen, Tournigand, Chibaudel, Falcone, Tebbutt, Punt, Hecht, Bokemeyer, Van Cutsem, Goldberg, Saltz, de Gramont, Sargent, Lenz Tags: Prognostic Studies, Chemotherapy Gastrointestinal Cancer Source Type: research

Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial [Breast Cancer]
Purpose Carpal tunnel syndrome (CTS) occurs when the median nerve is compressed at the wrist in the carpal tunnel. It has been suggested that hormonal risk factors may be involved in the pathogenesis of CTS, and a higher incidence of CTS has been reported in randomized clinical trials with aromatase inhibitors (AIs) compared with tamoxifen. Patients and Methods This was an exploratory analysis of the International Breast Cancer Intervention Study II, a double-blind randomized clinical trial in which women at increased risk of breast cancer were randomly assigned to receive anastrozole or placebo. This is the first report ...
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Spagnolo, Sestak, Howell, Forbes, Cuzick Tags: Hormonal Therapy Breast Cancer Source Type: research

Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer [Breast Cancer]
Conclusion We did not find racial disparities in ODX testing for node-negative patients for whom ODX testing is guideline recommended and widely covered by insurers. However, our findings suggest that a newer, non–guideline-concordant application of ODX testing for node-positive breast cancer was accessed less by black women than by non-black women, reflecting more guideline concordant care among black women. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Roberts, Weinberger, Dusetzina, Dinan, Reeder-Hayes, Carey, Troester, Wheeler Tags: Chemotherapy, Quality of Care Breast Cancer Source Type: research

Extended Survival and Prognostic Factors for Patients With ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastasis [Radiation Oncology]
Purpose We performed a multi-institutional study to identify prognostic factors and determine outcomes for patients with ALK-rearranged non–small-cell lung cancer (NSCLC) and brain metastasis. Patients and Methods A total of 90 patients with brain metastases from ALK-rearranged NSCLC were identified from six institutions; 84 of 90 patients received radiotherapy to the brain (stereotactic radiosurgery [SRS] or whole-brain radiotherapy [WBRT]), and 86 of 90 received tyrosine kinase inhibitor (TKI) therapy. Estimates for overall (OS) and intracranial progression-free survival were determined and clinical prognostic fac...
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Johung, Yeh, Desai, Williams, Lautenschlaeger, Arvold, Ning, Attia, Lovly, Goldberg, Beal, Yu, Kavanagh, Chiang, Camidge, Contessa Tags: Radiation Oncology Source Type: research

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group [Pediatric Oncology]
Purpose Patients with metastatic rhabdomyosarcoma (RMS), except those younger than 10 years with embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%. The main goal of this study was to improve outcome of patients with metastatic RMS by dose intensification with interval compression, use of the most active agents determined in phase II window studies, and use of irinotecan as a radiation sensitizer. Patients and Methods Patients with metastatic RMS received 54 weeks of therapy: blocks of therapy with vincristine/irinotecan (weeks 1 to 6, 20 to 25, and 47 to 52), interval compression with v...
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Weigel, Lyden, Anderson, Meyer, Parham, Rodeberg, Michalski, Hawkins, Arndt Tags: Rhabdomyosarcoma & Soft Tissue Sarcoma, Chemotherapy, Rhabdo & Other Soft Tissue Sarcomas: Pediatric Oncology Source Type: research

Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies [Phase I and Clinical Pharmacology]
Conclusion Patients with mild renal dysfunction by FDA criteria have routinely been enrolled onto phase I studies of antineoplastics without clinically meaningful increase in the risk of toxicity. In future oncology renal dysfunction trials based on the FDA classification, the FDA mild group may only need to be activated when the moderate and normal groups differ substantially in tolerability or pharmacokinetics. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Beumer, Ding, Tawbi, Lin, Viluh, Chatterjee, Rinker, Chow, Ivy Tags: Clinical Trials, Phase I and Clinical Pharmacology, Statistics in Oncology Source Type: research

CNS Metastases in Patients With Non-Small-Cell Lung Cancer and ALK Gene Rearrangement [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Shi, Dicker Tags: Brain Tumors, Combined Modality EDITORIALS Source Type: research

Metastatic Rhabdomyosarcoma: Still Room for Improvement [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Wexler Tags: Rhabdomyosarcoma & Soft Tissue Sarcoma, Combined Modality EDITORIALS Source Type: research

Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs [EDITORIALS]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Rudek, Graham, Ratain Tags: EDITORIALS Source Type: research

Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Browning, Huckleberry, Barrow, Restauri, Kemme, Cool, Weyant, Franklin, Camidge Tags: Diagnosis & Staging, Surgery, Imaging, Pathology, CT DIAGNOSIS IN ONCOLOGY Source Type: research

Management of Posterior Reversible Encephalopathy Syndrome Induced by Carfilzomib in a Patient With Multiple Myeloma [DIAGNOSIS IN ONCOLOGY]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - January 5, 2016 Category: Cancer & Oncology Authors: Cai, Bhattacharyya, Plitt, Raibagkar, LaBuzetta, Schleicher, Munshi, Klein Tags: Supportive Care, Chemotherapy, MRI DIAGNOSIS IN ONCOLOGY Source Type: research

Cancer Genomics: Diversity and Disparity Across Ethnicity and Geography [REVIEW ARTICLES]
Ethnic and geographic differences in cancer incidence, prognosis, and treatment outcomes can be attributed to diversity in the inherited (germline) and somatic genome. Although international large-scale sequencing efforts are beginning to unravel the genomic underpinnings of cancer traits, much remains to be known about the underlying mechanisms and determinants of genomic diversity. Carcinogenesis is a dynamic, complex phenomenon representing the interplay between genetic and environmental factors that results in divergent phenotypes across ethnicities and geography. For example, compared with whites, there is a higher in...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Tan, Mok, Rebbeck Tags: REVIEW ARTICLES Source Type: research

Infection and Cancer: The Case of Hepatitis B [REVIEW ARTICLES]
This article is divided into four parts: In the first part, an overview is given on the epidemiologic data and risk factors of HCC development in patients with chronic hepatitis B. In the second part, recent progress on the anti-HBV strategies for preventing HCC is updated. In the third part, approaches to improve the outcomes of established HBV-related HCC are covered. These methods include surveillance strategies to identify asymptomatic HCC among patients with chronic HBV infection, and use of antiviral treatment to avoid HBV reactivation during treatment for HCC and reduce the recurrence of HCC after curative treatment...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Chan, Wong, Qin, Chan Tags: Cancer Etiology, Epidemiology REVIEW ARTICLES Source Type: research

The American Society of Clinical Oncology's Efforts to Support Global Cancer Medicine [REVIEW ARTICLES]
This article reviews current ASCO activities in the international arena and its future plans in global oncology. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Hortobagyi, El-Saghir, Cufer, Cazap, de Guzman, Othieno-Abinya, Sanchez, Pyle Tags: Quality of Care, Policy Analysis, Quality of Care REVIEW ARTICLES Source Type: research

Proposing Essential Medicines to Treat Cancer: Methodologies, Processes, and Outcomes [REVIEW ARTICLES]
Conclusion The list of medications proposed, and the ability to link each recommended medicine to specific diseases, should allow public officials to apply resources most effectively in developing and supporting nascent or growing cancer treatment programs. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Shulman, Wagner, Barr, Lopes, Longo, Robertson, Forte, Torode, Magrini Tags: REVIEW ARTICLES Source Type: research

Provision of Palliative Care in Low- and Middle-Income Countries: Overcoming Obstacles for Effective Treatment Delivery [REVIEW ARTICLES]
Despite being declared a basic human right, access to adult and pediatric palliative care for millions of individuals in need in low- and middle-income countries (LMICs) continues to be limited or absent. The requirement to make palliative care available to patients with cancer is increasingly urgent because global cancer case prevalence is anticipated to double over the next two decades. Fifty percent of these cancers are expected to occur in LMICs, where mortality figures are disproportionately greater as a result of late detection of disease and insufficient access to appropriate treatment options. Notable initiatives i...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Hannon, Zimmermann, Knaul, Powell, Mwangi-Powell, Rodin Tags: Palliative Care REVIEW ARTICLES Source Type: research

Global Pediatric Oncology: Lessons From Partnerships Between High-Income Countries and Low- to Mid-Income Countries [REVIEW ARTICLES]
Partnerships between medical institutions in high-income countries (HICs) and low- to mid-income countries (LMICs) have succeeded in initiating and expanding pediatric cancer control efforts. The long-term goal is consistently a sustainable national pediatric cancer program. Here, we review the elements required for successful implementation, development, and long-term sustainability of pediatric cancer programs in LMICs that first arise as partnerships with institutions in HICs. Although plans must be adapted to each country's resources, certain components are unfailingly necessary. First, an essential step is provision o...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Ribeiro, Antillon, Pedrosa, Pui Tags: REVIEW ARTICLES Source Type: research

Implementation Science for Global Oncology: The Imperative to Evaluate the Safety and Efficacy of Cancer Care Delivery [REVIEW ARTICLES]
Conclusion Implementation science is both critical and feasible in evaluating, improving, and supporting effective expansion of cancer care in resource-limited settings. In ideal circumstances, it should be a prospective program, established early in the lifecycle of a new cancer treatment program and should be an integrated and continual process. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Tapela, Mpunga, Karema, Nzayisenga, Fadelu, Uwizeye, Hirschhorn, Muhimpundu, Balinda, Amoroso, Wagner, Binagwaho, Shulman Tags: Cancer Etiology, Environmental Risks, Behavioral and Lifestyle Risk Factors, Chemoprevention studies, Cost Effectiveness, Quality of Care, Policy Analysis, Ethics REVIEW ARTICLES Source Type: research

Medical Education and Training: Building In-Country Capacity at All Levels [REVIEW ARTICLES]
Poorly trained workers and limited workforce capacity contribute immensely to barriers in cancer control in low- and middle-income countries (LMICs). Because of an increasing disease burden and the gap in trained personnel, it is critical that LMICs must develop appropriate in-country training programs at all levels to adequately address their cancer-related outcomes. The training in LMICs of cancer health personnel should address priority cancer diseases in the specific country by developing caregivers, trainers, researchers, and administrators at all levels of health care and all cadres of staff, from the community level...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Chite Asirwa, Greist, Busakhala, Rosen, Loehrer Tags: Quality of Care REVIEW ARTICLES Source Type: research

Establishing and Delivering Quality Radiation Therapy in Resource-Constrained Settings: The Story of Botswana [Radiation Oncology]
There is a global cancer crisis, and it is disproportionately affecting resource-constrained settings, especially in low- and middle-income countries (LMICs). Radiotherapy is a critical and cost-effective component of a comprehensive cancer control plan that offers the potential for cure, control, and palliation of disease in greater than 50% of patients with cancer. Globally, LMICs do not have adequate access to quality radiation therapy and this gap is particularly pronounced in sub-Saharan Africa. Although there are numerous challenges in implementing a radiation therapy program in a low-resource setting, providing more...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Efstathiou, Heunis, Karumekayi, Makufa, Bvochora-Nsingo, Gierga, Suneja, Grover, Kasese, Mmalane, Moffat, von Paleske, Makhema, Dryden-Peterson Tags: Radiation Oncology Source Type: research

Oncologic Care and Pathology Resources in Africa: Survey and Recommendations [REVIEW ARTICLES]
The connection of a clinician who identifies a patient with signs and symptoms of malignancy to an oncologist who has the tools to treat a patient's cancer requires a diagnostic pathology laboratory to receive, process, and diagnose the tumor. Without an accurate classification, nothing is known of diagnosis, prognosis, or treatment by the clinical team, and most important, the patient is left scared, confused, and without hope. The vast majority of deaths from malignancies occur in sub-Saharan Africa primarily as a result of lack of public awareness of cancer and how it is diagnosed and treated in the setting of a severe ...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Nelson, Milner, Rebbeck, Iliyasu Tags: REVIEW ARTICLES Source Type: research

Structural Barriers to Diagnosis and Treatment of Cancer in Low- and Middle-Income Countries: The Urgent Need for Scaling Up [REVIEW ARTICLES]
Noncommunicable diseases are now recognized by the United Nations and WHO as a major public health crisis. Cancer is a main part of this problem, and health care systems are facing a great challenge to improve cancer care, control costs, and increase systems efficiency. The disparity in access to care and outcomes between high-income countries and low- and middle-income countries is staggering. The reasons for this disparity include cost, access to care, manpower and training deficits, and a lack of awareness in the lay and medical communities. Diagnosis and treatment play an important role in this complex environment. In ...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Cazap, Magrath, Kingham, Elzawawy Tags: REVIEW ARTICLES Source Type: research

Global Health Equity: Cancer Care Outcome Disparities in High-, Middle-, and Low-Income Countries [REVIEW ARTICLES]
Breakthroughs in our global fight against cancer have been achieved. However, this progress has been unequal. In low- and middle-income countries and for specific populations in high-income settings, many of these advancements are but an aspiration and hope for the future. This review will focus on health disparities in cancer within and across countries, drawing from examples in Kenya, Brazil, and the United States. Placed in context with these examples, the authors also draw basic recommendations from several initiatives and groups that are working on the issue of global cancer disparities, including the US Institute of ...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: de Souza, Hunt, Asirwa, Adebamowo, Lopes Tags: Outcomes Research REVIEW ARTICLES Source Type: research

A Vision for Global Cancer Medicine: Pursuing the Equity of Chance [REVIEW ARTICLES]
At the turn of the century, some claimed that HIV/AIDS was a disease that could not be managed in low-income settings. It was argued that "poor people would not comply with treatment," and that treatment was too expensive and too complicated to deliver. But over the past two decades, data on outcomes have thoroughly disproved this myth. Similar arguments have more recently been made about cancer treatment: chemotherapy was said to be too toxic and too costly and that it required administration expertise beyond that available in low-income settings. We argue that these claims are similarly rooted in ideology rathe...
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Binagwaho, Wagner, Farmer Tags: REVIEW ARTICLES Source Type: research

Special Issue on Global Cancer Medicine [SPECIAL SERIES OVERVIEW]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 28, 2015 Category: Cancer & Oncology Authors: Shulman, Mok Tags: SPECIAL SERIES OVERVIEW Source Type: research

Erratum [erratum]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Tags: ERRATUM Source Type: research

Patients Who Receive Androgen Deprivation Therapy Risk Adverse Cognitive Changes [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Gardiner, Yaxley, Pakenham, Green, Mactaggart, Watson, Swanson, Nicol Tags: CORRESPONDENCE Source Type: research

Reply to A. Fiorentino et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Bellon Tags: CORRESPONDENCE Source Type: research

Personalized--Not Omitted--Radiation Oncology for Breast Cancer [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Fiorentino, Mazzola, Ricchetti, Fersino, Giaj Levra, Alongi Tags: CORRESPONDENCE Source Type: research

Reply to L. Gianni et al [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Hershman, Unger Tags: CORRESPONDENCE Source Type: research

Omega-3 Fatty Acids for Aromatase Inhibitor-Induced Musculoskeletal Pain: Anything Other Than a Placebo Effect? [CORRESPONDENCE]
(Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - December 17, 2015 Category: Cancer & Oncology Authors: Gianni, Arcangeli, Tamburini, Tassinari Tags: CORRESPONDENCE Source Type: research